摘要
本文探讨了表没食子酸儿茶素没食子酸酯(epigallocatechin gallate,EGCG)联合顺铂(cisplatin,CDDP)对人骨肉瘤MG-63细胞生长抑制作用及可能的机制。分别采用不同浓度梯度表没食子酸儿茶素没食子酸酯和顺铂单独及联合作用于MG-63细胞;CCK-8法检测细胞生长抑制率,显微镜观察细胞形态变化;Transwell小室法检测细胞侵袭数,划痕实验检测细胞迁移能力;Western blot检测相关蛋白Bax、Bcl-2、Bcl-xL、MMP-2、MMP-9、Caspase-3、cleaved Caspase-3表达情况。结果显示,骨肉瘤MG-63细胞的增殖、侵袭及迁移能力随表没食子酸儿茶素没食子酸酯及顺铂的剂量增加而降低(P<0.05),联合用药抑制作用更强;Bcl-2、Bcl-xL、MMP-2及MMP-9表达水平明显下调(P<0.05),Bax、Caspase-3、cleaved Caspase-3水平明显上调(P<0.05);与表没食子酸儿茶素没食子酸酯组、顺铂组单药应用相比,联合用药组MG-63细胞抑制比例最高,其相关蛋白表达量也更为显著。综上所述,表没食子酸儿茶素没食子酸酯能有效抑制人骨肉瘤MG-63细胞增殖并诱导细胞凋亡发生,与顺铂联合应用后效果更为明显。本研究结果为骨肉瘤的临床治疗提供了新的理论依据。
To investigate the effect of epigallocatechin gallate(EGCG)combined with cisplatin on cell proliferation of human osteosarcoma MG-63 cells and its possible mechanism.MG-63 cells were treated with different concentrations of EGCG and cisplatin alone or in combination.The cell growth inhibition rate was measured by CCK-8 morphology was observed by microscope,the Transwell chamber detects the number of cell invasions,and the scratch test detects the cell migration ability;Western blot detection of Bax,Bcl-2,Bcl-xL,MMP-2,MMP-9,Caspase-3 and cleaved Caspase-3.The results showed that the ability of proliferation,invasion and migration of MG-63 cells decreased with the increase of the dose of EGCG and cisplatin(P<0.05),and the combined drug inhibition was stronger;the expression levels of Bcl-2,Bcl-xL,MMP-2 and MMP-9 were significantly down-regulated(P<0.05),and the levels of Bax,Caspase-3 and cleaved Caspase-3 were significantly up-regulated(P<0.05);Compared with the gallic acid catechin gallate group and the monotherapy application of the platinum group,the MG-63 cells in the combination group had the highest inhibition rate,and the related protein expression was also more significant.To sum up,EGCG can effectively inhibit the proliferation of human osteosarcoma MG-63 cells and induce apoptosis.The effect is more obvious when combined with cisplatin.
作者
黄磊
邹日昌
宋嘉琪
罗超
殷嫦嫦
HUANG Lei;ZOU Ri-chang;SONG Jia-qi;LUO Chao;YIN Chang-chang(Graduate School of Medicine,Nanchang University;The Second Hospital Affiliated of Nanchang University,Nanchang 330006,China;Fuzhou Municipal Hospital,Fuzhou 344000,China;Basic Medical College of Jiujiang University,Jiujiang 332000,China)
出处
《天然产物研究与开发》
CAS
CSCD
北大核心
2020年第12期2101-2108,2114,共9页
Natural Product Research and Development
基金
江西省卫生健康委科技计划(20204253)。
